Related Experiment Video
Updated: Aug 16, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
CD25+ CD4+ regulatory T-cells in cancer
David C Linehan1, Peter S Goedegebuure
1Department of Surgery and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. linehand@wustl.edu
Abstract:
Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor environment. Our studies in a mouse pancreas cancer model suggest that the tumor actively promotes the accrual of Treg through several mechanisms involving activation of naturally occurring Treg as well as conversion of non-Treg into Treg. Our studies focus on further defining these mechanisms with the ultimate goal of designing strategies that block Treg-mediated suppression in cancer patients.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
